


1

2 **Fig. S1. mTORC1 remains active in fetal hepatocytes in low glucose, but not in**
 3 **adult hepatocytes, related to Fig. 1 and Fig. 2.**

4 **a** mTORC1 remains active when treated with AMPK activator MK-8722 or inhibitor
 5 BAY-3827 in BNL-CL2, followed by determining p-S6K levels by immunoblotting. **b**
 6 Fasted pregnant mice (fetuses of E18.5d) and 8-week female adult mice showed a

7 significant decrease of plasma glucose after 24 h fasting (from 9.3 to 4.4 mM in the
8 adults, from 11.3 to 3.5 mM in the pregnant mice, and from 3.5 to 2.1 mM in the fetus).
9 Blood samples were collected from adult mice (8-week-old; adult blood glucose),
10 pregnant mice (E18.5d; pregnant blood glucose), or embryos (E18.5d; fetal blood
11 glucose), after being fasted for 0 h or 24 h. Blood glucose levels were detected by a
12 portable human glucometer (Accu-Chek; Roche). Data are presented as mean \pm SEM,
13 $n = 20$ for each adult group of **b**, $n = 4$ for each pregnant group of **b**, $n = 16$ for fetal
14 random blood glucose group of **b**, $n = 21$ for fetal fasting 24 h group of **b**, with P values
15 calculated using two-way ANOVA, followed by Tukey. **c** The TFEB is translocated into
16 nucleus after starvation for 4 h detected by immunofluorescence and the relative
17 fluorescence intensity were shown (presented as mean \pm SEM, 25 mM $n = 32$, 0 mM n
18 = 37, with P values calculated using unpaired two-tailed Student's t -test). **d** mTORC1
19 remains associated with RAG in BNL-CL2 in low glucose. See also AML12 cells, as a
20 control, in which mTORC1 is not associated with RAG. **e–h** mTORC1 dissociates from
21 the lysosomes in low glucose conditions in adult hepatocytes. The AML12 adult
22 hepatocyte cell line (**e**, **g**) and primary adult hepatocytes (**f**, **h**) were glucose-starved for
23 4 h. Endogenous mTOR (labelled in green with rabbit anti-mTOR antibody, CST 2983T)
24 and the lysosome marker LAMP2 (labelled in red with rat anti-LAMP2 antibody,
25 Abcam AB13524) were then stained. Representative images are shown in **e** and **f**, and
26 the Pearson's overlap coefficients in **g** and **h** (presented as mean \pm SEM, 25 mM $n =$
27 28, 0 mM $n = 33$ of **g** or 25 mM $n = 29$, 0 mM $n = 30$ of **h**, with P values calculated
28 using unpaired two-tailed Student's t -test). **i–n** Glucose starvation does not affect the

29 lysosomal acidity in fetal hepatocytes. The BNL-CL2 (left panel of **i**, and **j**), primary
30 fetal hepatocytes (right panel of **i**, and **k**), AML12 (left panel of **l**, and **m**), and primary
31 adult hepatocytes (right panel of **l**, and **n**) were either glucose-starved for 4 h or treated
32 with 25 mM NH₄Cl, the lysosome inhibitor, as a control for 2 h. In contrast, low glucose
33 effectively inhibited v-ATPase in adult hepatocytes. The cells were incubated with 1
34 μM LysosensorTM Green DND-189 (Thermo L7535) for 30 min to detect the PH of
35 lysosomes. Representative images are shown in **i** and **l**, and the Mander's overlap
36 coefficients in **j**, **k**, and **m**, **n** (presented as mean ± SEM, *n* = 25 for 25 mM group of **j**,
37 *n* = 22 for 0 mM group of **j**, *n* = 21 for 25 mM + NH₄Cl group of **j**, *n* = 24 for 0 mM +
38 NH₄Cl group of **j**; *n* = 19 for each group of **k**, with *P* values calculated using two-way
39 ANOVA, followed by Tukey. *n* = 12 for each group of **m**, *n* = 10 for each group of **n**,
40 with *P* values calculated using unpaired two-tailed Mann-Whitney test (**m**), or unpaired
41 two-tailed Student's *t*-test (**n**)). The original western blots with protein ladder are shown
42 in Supplementary Data S1. ns, not significant (*P* > 0.05).



43

44 **Fig. S2. Constitutively active v-ATPase-Ragulator-RAG axis maintains mTORC1**

45 **activity in fetal hepatocytes in low glucose, related to Fig. 2.**


46 **a, b** Forced inhibition of v-ATPase in fetal hepatocytes by concanamycin A (conA)

47 effectively triggers the lysosomal translocation of AXIN. BNL-CL2 were either

48 glucose-starved or treated with 1 μ M Concanamycin A, the v-ATPase inhibitor, as a
49 control for 6 h. Endogenous AXIN1 (labeled in green with goat anti-AXIN1 antibody,
50 Santa Cruz Biotechnology SC-8567) and the lysosome marker LAMP2 (labeled in red
51 with rat anti-LAMP2 antibody, Abcam AB13524) were then stained. Representative
52 images are shown in **a**, and the Mander's overlap coefficients in **b** (presented as mean
53 \pm SEM, $n = 20$ for each group, with P values calculated using two-way ANOVA,
54 followed by Tukey). **c–f** mTORC1 dissociates from the lysosomes in amino acid
55 deficiency conditions in fetal hepatocytes. The BNL-CL2 (**c**, **d**) and primary fetal
56 hepatocytes (**e**, **f**) were either glucose-starved or amino acid-starved for 2 h.
57 Endogenous mTOR (labeled in green with rabbit anti-mTOR antibody, CST 2983T)
58 and the lysosome marker LAMP2 (labeled in red with rat anti-LAMP2 antibody, Abcam
59 AB13524) were then stained. Representative images are shown in **c** and **e**, and the
60 Pearson's overlap coefficients are shown in **D** and **F** (presented as mean \pm SEM, $n = 41$
61 for + Glucose + Amino acid group of **d**, $n = 41$ for - Glucose - Amino acid group of **d**,
62 $n = 51$ for + Glucose - Amino acid group of **d**, $n = 56$ for - Glucose + Amino acid group
63 of **d**; $n = 58$ for + Glucose + Amino acid group of **f**; $n = 35$ for - Glucose - Amino acid
64 group of **f**; $n = 33$ for + Glucose - Amino acid group of **f**; $n = 48$ for - Glucose + Amino
65 acid group of **f**, with P values calculated using two-way ANOVA, followed by Tukey).

66 **g–j** Maternal fasting does not decrease the levels of amino acids, such as leucine,
67 glutamine, arginine, and asparagine, all of which can regulate mTORC1 activity, in the
68 fetal liver. Liver tissues were collected from E18.5d fetal mice after the pregnant
69 females were fasted for 0 h or 24 h, followed by determination of amino acid levels

70 through HPLC-MS analysis. Fasting did not decrease the relative concentration of
71 leucine (**g**), glutamine (**h**), arginine (**i**), and asparagine (**j**) in fetal liver tissues between
72 the fasting and control groups (presented as mean \pm SEM, $n = 9$ for each group of **g–j**,
73 with P values calculated using unpaired two-tailed Student's t -test). ns, not significant
74 ($P > 0.05$).




75

76 **Fig. S3. The overall levels of most amino acids in the liver of E18.5 d fetal mice do**
 77 **not significantly change after the pregnant females being fasted, related to Fig. 2.**

78 **a–q** Liver tissues were collected from E18.5d fetal mice after the pregnant females were
 79 fasted for 0 h or 24 h, followed by the detection of the relative concentration of histidine
 80 (a), lysine (b), glycine (c), alanine (d), valine (e), isoleucine (f), proline (g),
 81 phenylalanine (h), tyrosine (i), tryptophan (j), serine (k), threonine (l), cystine (m),

82 methionine (**n**), s-adenosyl-methionine (**o**), aspartate (**p**), glutamate (**q**) in fetal liver
83 tissues between the fasting and control groups using HPLC-MS (presented as mean \pm
84 SEM, $n = 9$ for each group of **a–n**, **p**, **q**, except $n = 6$ for each group of **o**, with P values
85 calculated using unpaired two-tailed Student's t -test (**a-i**, **k-l**, **p**), or unpaired t test with
86 Welch's correction (**j**, **n**, **o**, **q**), or unpaired two-tailed Mann-Whitney test (**m**). ns, not
87 significant ($P > 0.05$).




88

89 **Fig. S4. Effects of physiological concentrations of insulin and glucagon on Akt and**
 90 **mTORC1, related to Fig. 2 and Fig. 3.**

91 **a–g** Maternal fasting does not inhibit AKT signaling in fetal livers. Adult mice or
 92 pregnant mice were fasted for 24 h and the insulin (**a**), IGF-1 (**b**), and IGF-2 (**c**)

93 concentrations in the serum of the fetuses were checked by ELISA. Fetal mice (E18.5d)
94 insulin (**d**) and the p-AKT levels in primary fetal hepatocytes (**e**) were also detected in
95 a series of fasted time (0, 4, 8 and 24 h) and refed group (fasted for 24 h followed refed
96 2 h was defined as refed group). Data in **a–d** are shown as mean \pm SEM; $n = 7$ (adult
97 mice of **a–c**), 5 (pregnant mice of **a–c**), or 11 (fetal mice of **a–c**) mice for each condition,
98 with P values calculated using unpaired two-tailed Student's t -test (**a–c**), except for
99 fetal mice (**a–c**) where unpaired two-tailed Mann-Whitney test is used. For **d**, fetal mice
100 fasting 0 h and 24 h: $n = 15$; other fetal mice groups with different fasting time: $n = 6$,
101 with P values calculated using two-way ANOVA, followed by Tukey. For **f**, adult
102 fasting 0 h: $n = 11$; adult fasting 4 h and 8 h: $n = 5$: adult fasting 24 h: $n = 13$, adult
103 refed: $n = 6$, with P values calculated using two-way ANOVA, followed by Tukey. **h**
104 The glucagon concentration was detected at various developmental stages by ELISA.
105 Data are shown as mean \pm SEM; $n = 6$ in each group, with P values calculated by one-
106 way ANOVA, followed by Tukey. **i** Adding physiological concentration of glucagon
107 (30 pg/mL) and ultra-high glucagon (100 nM) to AML12, and giving corresponding
108 glucose starvation treatment for 4 h, mTORC1 of AML12 still showed sensitivity to
109 low glucose. The original western blots with protein ladder are shown in Supplementary
110 Data S1. ns, not significant ($P > 0.05$).




111

112 **Fig. S5. FBP and DHAP decrease in the fetal liver and adult livers in low glucose,**
 113 **related to Fig. 3.**

114 **a–l** Levels of FBP and DHAP are decreased in both fetal hepatocytes and adult
 115 hepatocytes in low glucose. BNL-CL2 (a–c), AML12 (d–f), PFH (g–i), and PAH (j–l)

116 were glucose-starved for 0 hour, 2 h, 4 h, 8 h, or 24 h, followed by determination of
117 FBP and DHAP by HPLC-MS. Data are presented as mean \pm SEM, $n = 5$ for each
118 condition of **a–f**, $n = 4$ for each condition of **g–i**, $n = 6$ for each condition of **j–l**, except
119 $n = 3$ for PFH 0 hour group of **g–i**. P values were calculated using one-way ANOVA,
120 followed by Dunnett's T3 multiple comparisons test (**a–d**, **j**), or followed by Dunnett's
121 multiple comparisons test (**e–i**); or using Kruskal-Wallis test, followed by Dunn's
122 multiple comparisons test (**k**, **l**). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, all compared with
123 0 hour group. **m–r** Levels of FBP and DHAP are decreased in the liver tissues of fetal
124 mice after maternal fasting (**m–o**), or in adult mouse livers (**p–r**). Liver tissues were
125 collected from pregnant mice embryos (E18.5 d; fetal liver tissue) or adult mice (8-
126 week-old; adult liver tissue), after being fasted for 0 h or 24 h. FBP and DHAP were
127 determined by HPLC-MS in liver tissue. Data are presented as mean \pm SEM. $n = 27$ for
128 fetal livers group of **m**, $n = 24$ for fetal livers fasting 24 h group of **m**; $n = 16$ for each
129 group of **n**, $n = 20$ for each group of **o**, $n = 8$ for each group of **p**; $n = 8$ for adult livers
130 group of **q**, $n = 7$ for adult livers fasting 24 h group of **q**; $n = 7$ for adult livers group of
131 **r**, $n = 8$ for adult livers fasting 24 h group of **r**; with P values calculated using unpaired
132 two-tailed Student's t -test (**q**, **r**), or unpaired t test with Welch's correction (**p**), or
133 unpaired two-tailed Mann-Whitney test (**m–o**). ns, not significant ($P > 0.05$).

134




135

136 **Fig. S6. Changes of glycolytic intermediates, other than FBP and DHAP, in hepatic**
 137 **cell lines after glucose starvation, related to Fig. 3.**

138 **a–n** The changes of glycolytic intermediates, other than FBP and DHAP, in BNL-CL2
 139 and AML12 cells after glucose starvation are shown. BNL-CL2 (**a–c, g–i, m**) and
 140 AML12 (**d–f, j–l, n**) cells were glucose-starved for 0 h, 2 h, 4 h, 8 h, or 24 h. HPLC

141 was used to determine glycolytic intermediates in these cells. Data are presented as
142 mean \pm SEM, $n = 5$ for each condition of **a–n**. P values were calculated using one-way
143 ANOVA, followed by Dunnett's T3 multiple comparisons test (**a, i**), or followed by
144 Dunnett's multiple comparisons test (**b–h, l–n**); or using Kruskal-Wallis test, followed
145 by Dunn's multiple comparisons test (**j, k**). * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; all
146 compared with 0 h group. ns, not significant ($P > 0.05$)




147

148 **Fig. S7. Changes of glycolytic intermediates, other than FBP and DHAP, in**
 149 **primary hepatocytes after glucose starvation, related to Fig. 3.**

150 **a–n** The changes of glycolytic intermediates, other than FBP and DHAP, in PFH and
 151 PAH cells after glucose starvation are shown. PFH (**a–c, g–i, m**) and PAH (**d–f, j–l, n**)
 152 cells were glucose-starved for 0 h, 2 h, 4 h, 8 h, or 24 h. HPLC was used to determine
 153 glycolytic intermediates in these cells. Data are presented as mean \pm SEM, $n = 4$ for

154 each condition of **a–c, g–i, m**, $n = 6$ for each condition of **d–f, j–l, n**, except $n = 3$ for
155 PFH 0 h group of **a–c, g–i, m**. P values were calculated using one-way ANOVA,
156 followed by Dunnett's T3 multiple comparisons test (**d, f, j, k**), or followed by Dunnett's
157 multiple comparisons test (**a, b, g-i, n**); or using Kruskal-Wallis test, followed by
158 Dunn's multiple comparisons test (**c, e, l, m**). $*P < 0.05$; $**P < 0.01$; $***P < 0.001$; all
159 compared with 0 h group. ns, not significant ($P > 0.05$).



160


161 **Fig. S8. Changes of glycolytic metabolites, other than FBP and DHAP, in the livers**

162 **of E18.5 d fetal mice after the pregnant females being fasted, related to Fig. 3.**

163 **a–n** Liver tissues collected from pregnant mouse embryos (E18.5d; fetal liver tissue)

164 or adult mice (8-week-old; adult liver tissue) after fasting for 0 h or 24 h were subjected

165 to HPLC to determine glycolytic intermediates. Data are presented as mean \pm SEM, $n =$
166 29 for fetal livers group of **a, b, j, k**, $n = 24$ for fetal livers fasting 24 h group of **a, b, j,**
167 **k**; $n = 23$ for fetal livers group of **c**, $n = 22$ for fetal livers fasting 24 h group of **c**; $n =$
168 24 for fetal livers group of **d**, $n = 19$ for fetal livers fasting 24 h group of **d**; $n = 25$ for
169 fetal livers group of **i**, $n = 23$ for fetal livers fasting 24 h group of **i**; $n = 8$ for each group
170 of **h, n**; $n = 7$ for each group of **l, m**. P values were calculated using unpaired two-tailed
171 Student's t -test (**c, d, g, h, n**), or unpaired t test with Welch's correction (**f, i, j, l, m**), or
172 unpaired two-tailed Mann-Whitney test (**a, b, e, k**). ns, not significant ($P > 0.05$).




173

174 **Fig. S9. Fetal AMPK is allosterically activated through the canonical, AMP-**
 175 **dependent mechanism, related to Fig. 3.**

176 **a** TRPV4 has the highest mRNA levels in BNL-CL2 cells (by transcriptomics). Data
 177 presented as mean \pm SEM, $n = 3$ for each group, with P values calculated by one-way
 178 ANOVA, followed by Dunnett's multiple comparisons test, all compared with TRPV4
 179 group. **b** TRPV4 has the highest mRNA levels in E18.5d fetal liver (by qPCR). Data
 180 presented as mean \pm SEM, $n = 7$ for each group, with P values calculated using Kruskal-

181 Wallis test, followed by Dunn's multiple comparisons test , all compared with TRPV4
182 group. **c** TRPV4 can be detected in BNL-CL2, AML12, PFH, and fetal liver tissues. **d**,
183 **e** Forced inhibition of TRPVs in fetal hepatocytes can inhibit the activity of v-ATPase.
184 The BNL-CL2 (**d**) was either glucose-starved (GS) or treated with 50 μ M BCTC, the
185 TRPV inhibitor, as a control + GS for 4 h. The cells were incubated with 1 μ M
186 LysosensorTM Green DND-189 (Thermo L7535) for 30 min to detect the PH of
187 lysosomes. Representative images are shown in **d**, and the relative intensity of
188 fluorescence in **e** was presented as mean \pm SEM, $n = 20$ for 25 mM group of **e**, $n = 20$
189 for GS 4 h group of **e**, $n = 20$ for GS 4 h + 50 μ M BCTC group of **e**, with P values
190 calculated using two-way ANOVA, followed by Tukey. **f**, **g** Forced inhibition of TRPVs
191 in fetal hepatocytes by BCTC effectively triggers the lysosomal translocation of AXIN
192 in fetal hepatocytes. BNL-CL2 cells were either glucose-starved for 4 h or treated with
193 500 μ M BCTC, the TRPV inhibitor, for 2 h. Endogenous AXIN1 (labelled in green with
194 goat anti-AXIN1 antibody, Santa Cruz Biotechnology SC-8567) and the lysosome
195 marker LAMP2 (labelled in red with rat anti-LAMP2 antibody, Abcam AB13524) were
196 then stained. Representative images are shown in **f**, and the Mander's overlap
197 coefficients in **g** (presented as mean \pm SEM, $n = 20$ for 25 mM group, $n = 20$ for GS 4
198 h group, $n = 21$ for GS 4 h + BCTC 500 μ M group, with P values calculated using two-
199 way ANOVA, followed by Tukey). **h**, **i** Glucose starvation significantly increases the
200 ratios of AMP:ATP and ADP:ATP in fetal hepatocytes. Liver tissues were collected
201 from pregnant mice embryos (E18.5d; fetal liver tissue) and adult mice (8-week-old;
202 adult liver tissue), after being fasted for 0 h or 24 h. HPLC was used to detect energy

203 levels in tissues (presented as mean \pm SEM, $n = 7$ for each adult group of **h, i**, $n = 11$
204 for each fetal group of **h, i** with P values calculated using two-way ANOVA, followed
205 by Tukey). The original western blots with protein ladder are shown in Supplementary
206 Data S1. ns, not significant ($P > 0.05$).




207

208 **Fig. S10. Levels of acetylated TRPV4-K608 are significantly higher in the fetal**
 209 **liver than in the adult liver, related to Fig. 3 and Fig. 4.**

210 **a** The protein level of TRPV4 in fetal liver tissues is lower than those in adult liver
 211 tissue. **b** The protein level of TRPV in PFH is lower than those in PAH. **c-k** Levels of

212 acetylated TRPV4-K608 are significantly higher in fetal liver than in adult liver, as
213 determined by quantitative mass spectrometry analysis. Quantitative modification mass
214 spectrometry detected a peptide segment containing K608-acetylation (TGTYSIMIQK
215 (+42.01)) and a peptide segment (GVPNPIDLLESTLYESSVVPK). The peak area
216 represents the relative abundance of each peptide segment in the sample. The peak area
217 ratio of TGTYSIMIQK (+42.01)/GVPNPIDLLESTLYESSVVPK represented the
218 relative level of acetylated TRPV4 (at K608 site) in different samples (presented as
219 mean \pm SEM, $n = 6$ (adult livers of **k**; **e**, **f**, **i**, **j**), $n = 3$ (newborn livers of **K**; **D**, **H**), $n =$
220 **3** (fetal livers of **k**; **c**, **g**), with P values calculated using Kruskal-Wallis test, followed
221 by Dunn's multiple comparisons test). **l**, **m** Qualitative mass spectrometry shows the
222 presence of acetylation modification at the K608 site of TRPV4 in BNL-CL2. TRPV4
223 was enriched from BNL-CL2 cells stably expressing HA-tagged TRPV4 using
224 immunoprecipitation. The original western blots with protein ladder are shown in
225 Supplementary Data S1. ns, not significant ($P > 0.05$).




226

227 **Fig. S11. Deacetylation of TRPV during intrauterine development confers**
 228 **sensitivity to low glucose, related to Fig. 4.**

229 **a** The K608 residue is highly conserved among different species and different members
 230 of the TRPV family. **b–d** v-ATPase inhibition can be observed in fetal hepatocytes

231 expressing TRPV4-K608R in low glucose conditions, as seen in adult cells. The cells
232 were incubated with 1 μ M LysoSensorTM Green DND-189 (Thermo L7535) for 30 min
233 to detect the PH of lysosomes. The BNL-CL2 cells stably expressing HA-tagged
234 TRPV4 WT (left panel of **b**, **c**) or HA-tagged TRPV4 K608R (right panel of **b**, **d**) were
235 glucose-starved for 4 h. Representative images are shown in **B??**, and the Mander's
236 overlap coefficients in **c**, **d** (presented as mean \pm SEM, $n = 21$ for 25mM group of **c**, n
237 = 22 for GS 4 h group of **c**, $n = 23$ for 25mM group of **d**, $n = 24$ for GS 4 h group of **d**,
238 with P values calculated using unpaired two-tailed Student's t -test) (**c**) or unpaired two-
239 tailed Mann-Whitney test (**d**). **e–h** The lysosomal translocation of AXIN can be
240 observed in fetal hepatocytes expressing TRPV4-K608R in low glucose conditions. The
241 BNL-CL2 cells stably expressing HA-tagged TRPV4 WT (**e**, **g**) or HA-tagged TRPV4
242 K608R (**f**, **h**) were glucose-starved for 4 h. Representative images are shown in **e**, **f** and
243 the Mander's overlap coefficients in **g**, **h** (presented as mean \pm SEM, $n = 17$ for 25 mM
244 group of **g**, $n = 16$ for 0 mM of **g**, $n = 17$ for 25 mM group of **h**, $n = 19$ for 0 mM group
245 of **h**, with P values calculated using unpaired two-tailed Student's t -test). **i**, **j** The
246 mutation of K608 does not affect the basal activity of TRPV4, but renders TRPV4 able
247 to be closed in fetal hepatocytes in low glucose conditions. BNL-CL2 cells stably
248 expressing TRPV4 K608R-GCaMP6s were glucose-starved for 4 h. TRPV4-GCaMP6s
249 were used to detect local calcium concentration, which can reflect whether TRPV4 is
250 closed or not. The intensities of the indicator were then determined. The result showed
251 that K608R-TRPV4, but not wildtype TRPV4, was closed in BNL-CL2 in low glucose
252 conditions. Statistical analysis data are shown as mean \pm SEM; $n = 20$ for TRPV4

253 K608R group of **j**, $n = 20$ for TRPV4 K608R GS 4 h group of **j**; P values calculated
254 using unpaired t test with Welch's correction (**j**). **k** The mutation of K608 of TRPV4
255 does not change its affinity with the FBP-unoccupied aldolase. The BNL-CL2 (fetal
256 hepatocytes) cells stably expressing HA-tagged TRPV4 K608R and Flag-tagged
257 aldolase were glucose-starved for 4 h. Cells were then lysed, and the lysates were
258 incubated with 20 μ M FBP for 12 h. The interaction between aldolase and TRPV4 in
259 the lysates was then determined by immunoprecipitation of HA-tag, followed by
260 immunoblotting. The original western blots with protein ladder are shown in
261 Supplementary Data S1. ns, not significant ($P > 0.05$).



262

263 **Fig. S12. Deacetylation of TRPV4 slightly decrease its protein stability, related to**

264 **Fig. 4.**

265 **a, b** The mutation of K608 of TRPV4 decreases its protein stability. BNL-CL2 (fetal

266 hepatocytes) cells stably expressing HA-tagged TRPV4-WT or TRPV4-K608R were

267 treated with cycloheximide (200 µg/ mL) for 0, 4, 8, 12, 16, 20 or 24 h, followed by

268 determination of HA-tagged TRPV4 protein level by immunoblotting. Data are

269 presented as mean ± SEM, *n* = 3, with *P* values calculated using two-way ANOVA,

270 followed by Tukey. BNL-CL2 (fetal hepatocytes) cells stably expressing HA-tagged


271 TRPV4-WT or TRPV4-K608R were treated with MG132 (10 µM/mL) for 24 h of **b**,

272 followed by determination of ubiquitin (abcam, ab134953) by immunoblotting. **c** The

273 mutation of TRPV4-K608 to Q does not change AML12 response to low glucose. The

274 AML12 (adult hepatocytes) cells stably expressing HA-tagged TRPV4-WT, TRPV4-

275 K608R or TRPV4-K608Q were glucose-starved for 4 h. Cells were then lysed, followed
276 by determination of p-S6K levels by immunoblotting. **d** The acetyl-CoA concentration
277 in fetal mice liver tissue is lower than in the adult liver tissue. Acetyl-CoA was
278 determined by HPLC-MS (presented as mean \pm SEM, $n = 6$ for each group, with P
279 values calculated using unpaired t test with Welch's correction). The original western
280 blots with protein ladder are shown in Supplementary Data S1. ns, not significant ($P >$
281 0.05)




282

283 **Fig. S13. Only knocking down P300 inhibits mTORC1 activity in low glucose of**
 284 **BNL-CL2 cells by screening all acetyltransferase, related to Fig. 4.**

285 **a–o** The shRNA of *Kat2a*, *Kat2b*, *Hat1*, *Atf2*, *Taf1*, *Kat5*, *Kat6a*, *Kat6b*, *Kat7*, *Ncoa-1*,
 286 *Ncoa-2*, *Ncoa-3*, *TAFII250*, *Gtf3c1* and *Clock* were designed and transfected into BNL-
 287 CL2 cells by Lentivirus, respectively. Cells were under starvation for 4 h, followed by

288 determination of phosphorylation of S6K (p-S6K) levels via immunoblotting. As a
289 control, rapamycin (100 nM, treatment for 1 hour) was used to inhibit S6K
290 phosphorylation. See also phosphorylation of AMPK α in these cells. The original
291 western blots with protein ladder are shown in Supplementary Data S1.




292

293 **Fig. S14. HDACs and SIRTs (except SIRT2 and SIRT7) does not change the**
 294 **mTORC1 activity in low glucose of BNL-CL2 cells, related to Fig. 4.**

295 **a-c** The ORF of *HDACs* (*HDAC1-HDAC11*) and *SIRTs* (*SIRT1-SIRT7*) fragments were
 296 ligated into the lentivirus vector *pBOBI*, and transfected into BNL-CL2 cells by
 297 lentivirus, respectively. Cells were under starvation for 4 h, followed by determination

298 of phosphorylation of S6K (p-S6K). As a control, rapamycin (100 nM, treatment for 1
299 hour) was used to inhibit S6K phosphorylation levels via immunoblotting. See also
300 phosphorylation of AMPK α in these cells. The original western blots with protein
301 ladder are shown in Supplementary Data S1.




302

303 **Fig. S15. Levels of acetylated TRPV4-K608 are significantly higher in the fetal**
 304 **liver than in the adult liver; ectopic expression of SIRT2 or SIRT7 notably reduced**
 305 **the levels of acetylated TRPV4-K608, related to Fig. 4.**

306 **a–h Levels of acetylated TRPV4-K608 are significantly higher in fetal liver than in**

307 adult liver; ectopic expression of SIRT2 or SIRT7 notably reduced the levels of
308 acetylated TRPV4-K608 as determined by quantitative mass spectrometry analysis.
309 Quantitative modification mass spectrometry detected a peptide segment containing
310 K608-acetylation (TGTYSIMIQQ (+42.01)) and a peptide segment
311 (GVPNPIDLLESTLYESSVVPQPK). The peak area represents the relative abundance
312 of each peptide segment in the sample. The peak area ratio of TGTYSIMIQQ
313 (+42.01)/GVPNPIDLLESTLYESSVVPQPK represented the relative level of
314 acetylated TRPV4 (at K608 site) in different samples (presented as mean \pm SEM, $n = 6$
315 (adult livers of **a**, **b**), $n = 3$ (BNL-CL2 of **c**, **d**), $n = 3$ (ectopic expression of SIRT2 in
316 BNL-CL2 of **e**, **f**), $n = 3$ (ectopic expression of SIRT7 in BNL-CL2 of **g**, **h**), with P
317 values calculated using unpaired two-tailed Student's t -test is used. Qualitative mass
318 spectrometry shows the presence of acetylation modification at the K608 site of TRPV4
319 in BNL-CL2. TRPV4 was enriched from BNL-CL2 cells stably expressing HA-tagged
320 TRPV4 using immunoprecipitation.




321

322 **Fig. S16. Levels of acetylated TRPV4-K608 decreases significantly when P300 is**
 323 **knocked down in the fetal BNL-CL2 cells, related to Fig. 4.**

324 **a, b** Levels of acetylated TRPV4-K608 are downregulated notably when P300 is
 325 knocked down in the fetal BNL-CL2 cells. shP300 significantly reduced the levels of
 326 acetylated TRPV4-K608 as determined by quantitative mass spectrometry analysis.
 327 Quantitative modification mass spectrometry detected a peptide segment containing
 328 K608-acetylation (TGTYSIMIQQK (+42.01)) and a peptide segment
 329 (GVPNPIDLLESTLYESSVVPGPK). The peak area represents the relative abundance
 330 of each peptide segment in the sample. The peak area ratio of TGTYSIMIQQK
 331 (+42.01)/GVPNPIDLLESTLYESSVVPGPK represented the relative level of
 332 acetylated trpv4 (at K608 site) in different samples (presented as mean \pm SEM, $n = 3$
 333 (shP300 of **a**), $n = 3$ (BNL-CL2 of **b**), with P values calculated using unpaired two-
 334 tailed Student's t -test is used. Qualitative mass spectrometry shows the presence of

335 acetylation modification at the K608 site of TRPV4 in BNL-CL2. TRPV4 was enriched
336 from BNL-CL2 cells stably expressing HA-tagged TRPV4 using immunoprecipitation.



337


338 **Fig. S17. Phenotypes of fetal mice with TRPV4-K608R expression, related to Fig.**

339 **5.**

340 **a–c** Genotypes of fetal liver samples. **d, e** The knock-in of TRPV4-WT or K608R does

341 not influence TRPV4 basal protein expression in fetal livers. Liver tissues collected

342 from E18.5d fetal mice with liver-specific transgenic mice WT (T4-WT⁺ & Alb-cre⁻),
343 TRPV4-WT-LKI (T4-WT⁺ & Alb-cre⁺), WT (K608R⁺ & Alb-cre⁻) and TRPV4-K608R-
344 LKI (K608R⁺ & Alb-cre⁺). Data are shown as mean \pm SEM, $n = 3$ in each group of ϵ ,
345 with P values calculated using one-way ANOVA, followed by Tukey. The original
346 western blots with protein ladder are shown in Supplementary Data S1. ns, not
347 significant ($P > 0.05$).




348

349 **Fig. S18. Levels of acetylated TRPV4-K608 are significantly lower in the TRPV4-**
 350 **K608R-LKI fetal liver, related to Fig. 5.**

351 **a–m** Levels of acetylated TRPV4-K608 are significantly higher in TRPV4-WT-LKI
 352 fetal liver than in TRPV4-K608R-LKI liver, as determined by quantitative mass
 353 spectrometry analysis. Quantitative modification mass spectrometry detected a peptide

354 segment containing K608-acetylation (TGTYSIMIQQ (+42.01)) and a peptide segment
355 (GVPNPIDLLESTLYESSVVPQPK). The peak area represents the relative abundance
356 of each peptide segment in the sample. The peak area ratio of TGTYSIMIQQ
357 (+42.01)/GVPNPIDLLESTLYESSVVPQPK represented the relative level of
358 acetylated TRPV4 (at K608 site) in different samples (presented as mean \pm SEM, $n = 3$
359 (WT-LKI fetal livers of **a, b, c; g, h, i; m**), $n = 3$ (K608R-LKI fetal livers of **d, e, f; j,**
360 **k, l; m**), with P values calculated using unpaired two-tailed Student's t -test is used).




361

362 **Fig. S19. Deacetylation of TRPV4 decrease the albumin, HGF, and IGF-1 proteins**
 363 **concentration in fetal hepatocytes, related to Fig. 5.**

364 **a** Approximately 18% (2/11) of embryos with specific K608R-TRPV4 expression in
 365 the liver died during intrauterine development. **b–d** p-APMK levels showed no obvious

366 differences in WT and TRPV4-K608R-LKI group (**b**), and in WT and TRPV4-WT-LKI
367 group (**b**). Data are shown as mean \pm SEM, $n = 15$ for WT, $n = 8$ for TRPV4-K608R-
368 LKI group of **c**; $n = 9$ for WT, $n = 5$ for TRPV4-WT-LKI of **d** with P values calculated
369 using unpaired two-tailed Student's t -test (**c**) or unpaired t test with Welch's correction
370 (**d**). **e-j** TRPV4-K608R dominantly inhibits albumin, HGF, and IGF-1 in fetal livers.
371 Liver tissues collected from E18.5d fetal mice with liver-specific TRPV4-K608R (Fig.
372 **5a; e, g, i**) or wildtype TRPV4 (Fig **5b; f, h, j**) knocked-in were lysed, followed by
373 determination of albumin, HGF, and IGF-1 levels by immunoblotting. Statistical
374 analysis data are shown as mean \pm SEM, $n = 15$ for WT group of **e, g, i**; $n = 8$ for
375 TRPV4-K608R-LKI group of **e, g, i**; $n = 17$ for WT group of **f, h, j**; $n = 5$ for TRPV4-
376 WT-LKI group of **f, h, j** with P values calculated using unpaired two-tailed Student's t -
377 test (**e, f, i, j**), or unpaired t test with Welch's correction (**g**), or unpaired two-tailed
378 Mann-Whitney test (**h**). **k-n** The fetal liver weight and the fetal liver weight/body
379 weight of TRPV4-K608R-LKI mice decrease significantly. Data are shown as mean \pm
380 SEM, $n = 7$ for $T4-K608R^+ \& Alb-cre^-$ of **k, l**, $n = 10$ for $T4-K608R^- \& Alb-cre^+$ of **k, l**;
381 $n = 8$ for $T4-K608R^- \& Alb-cre^-$ of **k, l**, $n = 11$ for $T4-K608R^+ \& Alb-cre^+$ of **k, l**; $n = 7$
382 for $T4-WT^+ \& Alb-cre^-$ of **m, n**, $n = 7$ for $T4-WT^- \& Alb-cre^+$ of **m, n**, $n = 9$ for $T4-WT^-$
383 $\& Alb-cre^-$ of **m, n**, $n = 9$ for $T4-WT^+ \& Alb-cre^+$ of **m, n**, with P values calculated using
384 one-way ANOVA, followed by Tukey (**k, l, n**); or using Kruskal-Wallis test, followed
385 by Dunn's multiple comparisons test (**m**). **o** Proteomics data demonstrated that protein
386 level decrease significantly in the TRPV4-K608R-LKI mice fetal liver tissues. The fetal
387 liver tissues from $T4-WT^+ \& Alb-cre^-$, $T4-WT^+ \& Alb-cre^+$, $K608R^+ \& Alb-cre^-$ and

388 *K608R*⁺ & *Alb-cre*⁺ (E18.5d) were analyzed by proteomics. **p, q** In addition to liver
389 abnormalities, the body protein concentration (removed the liver) of K608R-LKI fetal
390 mice decreased, while that of WT-LKI fetal mice did not decrease. Data are shown as
391 mean ± SEM, *n* = 14 for WT of **p**, *n* = 6 for *T4-K608R*⁺ & *Alb-cre*⁺ of **p, i**; *n* = 9 for
392 WT of **q**, *n* = 8 for *T4-WT*⁺ & *Alb-cre*⁺ of **q**, with *P* values calculated using unpaired
393 two-tailed Student's *t*-test. The original western blots with protein ladder are shown in
394 Supplementary Data S1. ns, not significant (*P* > 0.05).




395

396 **Fig. S20. Deacetylation of TRPV4 has little effect on liver hemoglobin, liver**
 397 **erythropoietin and blood glucose levels in fetus, but decrease the proliferation rate**
 398 **in fetal hepatocytes, related to Fig. 5.**

399 **a, b** The knockin of TRPV4-K608R significantly decreases fetal hepatocytes
 400 proliferation in liver tissue. Liver tissues collected from E18.5d fetal mice with liver-
 401 specific transgenic mice WT ($T4-WT^+$ & $Alb-cre^-$), TRPV4-WT-LKI ($T4-WT^+$ & $Alb-$
 402 cre^+), WT ($K608R^+$ & $Alb-cre^-$) and TRPV4-K608R-LKI ($K608R^+$ & $Alb-cre^+$). Data
 403 are shown as mean \pm SEM, $n = 6$ in each group of **b**, with P values calculated using

404 one-way ANOVA, followed by Tukey. **c**, **d** TRPV4-K608R has little effect on fetal
405 blood glucose levels. Data are shown as mean \pm SEM, $n = 7$ for *T4-K608R⁺* & *Alb-cre⁻*
406 of **c**, $n = 10$ for *T4-K608R⁻* & *Alb-cre⁺* of **c**; $n = 8$ for *T4-K608R⁻* & *Alb-cre⁻* of **c**, $n = 11$
407 for *T4-K608R⁺* & *Alb-cre⁺* of **c**; $n = 7$ for *T4-WT⁺* & *Alb-cre⁻* of **d**, $n = 7$ for *T4-WT⁻* &
408 *Alb-cre⁺* of **d**, $n = 9$ for *T4-WT⁻* & *Alb-cre⁻* of **d**, $n = 9$ for *T4-WT⁺* & *Alb-cre⁺* of **d**, with
409 *P* values calculated using one-way ANOVA, followed by Dunnett's T3 multiple
410 comparisons test (**c**) or Tukey (**d**). **e-j** TRPV4-K608R has little effect on hemoglobin
411 and erythropoietin levels. Liver tissues collected from E18.5d fetal mice with liver-
412 specific TRPV4-K608R (Fig. 5a; **e**, **g**, **i**) or wildtype TRPV4 (Fig. 5b; **f**, **h**, **j**) knocked
413 in were lysed, followed by determination of hemoglobin α/γ and erythropoietin levels
414 by immunoblotting. Statistical analysis data are shown as mean \pm SEM, $n = 15$ for WT
415 group of **e**, **g**, **i**; $n = 8$ for TRPV4-K608R-LKI group of **e**, **g**, **i**; $n = 17$ for WT group of
416 **f**, **h**, **j**; $n = 5$ for TRPV4-WT-LKI group of **f**, **h**, **j** with *P* values calculated using unpaired
417 two-tailed Student's *t*-test. ns, not significant ($P > 0.05$).



418

419 **Fig. S21. Rapamycin administration in wild-type embryos, which inhibits**
 420 **mTORC1 in fetal livers, recapitulates the phenotypes observed in the K608R-**
 421 **TRPV4-expressing embryos, related to Fig. 5.**

422 **a–e** Rapamycin administration in wild-type embryos resembles the phenotypes
 423 observed in the K608R-TRPV4-expressing embryos. Rapamycin leads to a decrease in
 424 liver weight (**c**), fetal liver weight/fetal weight (**d**), and an increase in intrauterine
 425 mortality rate (**e**) in fetal mice. Statistical analysis data are shown as mean \pm SEM, $n =$
 426 30 for control group of **b–d**, $n = 28$ for 5 mg/kg rapamycin group **b–d**, $n = 19$ for 10
 427 mg/kg rapamycin group of **b–d**; $n = 33$ for control group of **e**, $n = 34$ for 5mg/kg
 428 rapamycin group of **e**, $n = 36$ for 10 mg/kg rapamycin group of **e**, with P values

429 calculated using one-way ANOVA, followed by Dunnett's T3 multiple comparisons test
430 **(b)**, Tukey **(c)** or using Kruskal-Wallis test, followed by Dunn's multiple comparisons
431 test **(d)**, or Pearson chi-square **(e)**, whole group, comparison between 5mg/kg rapamycin
432 group and 10 mg/kg rapamycin group), or followed by Fisher's exact test **(e)**,
433 comparison between control group and 5mg/kg rapamycin group, comparison between
434 control group and 10mg/kg rapamycin group). **f** Rapamycin administration in wild-type
435 embryos inhibits mTORC1 in fetal livers, as assessed by the p-S6K levels via
436 immunoblotting. **g** Blockage of the mTORC1 signaling by knocking out Raptor in the
437 fetal liver is unsuccessful. The protein levels of Raptor remained mostly unaffected in
438 the fetal liver (Raptor^{F/F} & Alb-cre⁻ vs Raptor^{F/F} & Alb-cre⁺). **h, i** Genotyping of Alb-
439 cre⁻, Raptor^{F/F} and Alb-cre⁺, Raptor^{F/F} fetal mice. Alb-cre⁺, Raptor^{F/-} male mice were
440 mated with Raptor^{F/F} female mice to obtain Raptor^{F/F} & Alb-cre⁻, Raptor^{F/F} & Alb-cre⁺
441 fetal mice. The original western blots with protein ladder are shown in Supplementary
442 Data S1. ns, not significant ($P > 0.05$).